Navigation Links
Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs

Researchers from MetroHealth Medical Center and Case Western Reserve University in Cleveland, OH found that treating expectant mothers// who have had previous spontaneous preterm births with 17 Alpha Hydroxyprogesterone caproate (17P) and reducing the incidence of another preterm birth would consequently reduce both short-term and lifetime medical costs in offspring by $2 billion per year. The results of their study are reported in the March issue of the American Journal of Obstetrics & Gynecology.

"In the United States, preterm birth is the leading cause of neonatal deaths and the leading cause of pediatric neuro-developmental disability, including cerebral palsy and mental retardation. It is also an important cause of chronic lung disease, visual impairment, and other chronic illness in children." That statement, from an editorial authored by Joanne Armstrong, MD, MPH, of Baylor College of Medicine in Houston, TX, and Senior Medical Director, Women's Health for Aetna, also appears in the March issue of the American Journal of Obstetrics & Gynecology. It reinforces why the results of the study are particularly significant.

Combining data from six studies of the costs of preterm births with estimates of the effectiveness of 17P in seven other studies, the investigators determined that initial neonatal hospital costs could be reduced by $3800 per woman treated and could lead to a reduction in lifetime medical costs of $15,900 per child. Senior investigator Jennifer Bailit MD, MPH, of the MetroHealth Medical Center states, "If the eligible population was universally treated with 17P, discounted lifetime medical costs of their offspring could be reduced by more than $2 billion annually. The potential societal savings from Medicaid coverage of 17P are substantial."

Dr. Armstrong continues in the editorial, "As more evidence accumulates about the effectiveness of 17P to prevent preterm birth, the current work of Bailit and colleagues p rovides valuable information about the magnitude of the cost benefit of 17P that can help inform health policy decisions and guide resource investments in the prevention of preterm birth." At the present time 17P is not yet FDA approved for this indication.

The Journal editors add, "We urge readers to share both Dr. Bailit's analysis and Dr. Armstrong's commentary with colleagues and third-party payers."

Source-Eurekalert/B
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Gene Therapy shows promise in treating Hemophilia
4. "Make AIDS Therapy affordable" - Physicians demand
5. Hormone replacement Therapy a headache
6. Simple Therapy
7. Therapy for stopping the spread of cancer cells
8. Gene Therapy Destroys Pancreatic Cancer Cells
9. Letrozole Beats Tamoxifen in Breast Cancer Therapy
10. Garlic Supplements Impede HIV Therapy
11. Gene Therapy For Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... home care professionals, today announced that it has raised $1.675 M in seed ... , Rethink Education, Lumina Foundation, and Techstars Venture Capital Fund are the company’s ...
(Date:8/17/2017)... ... 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, has been ... been included in the Inc. 5000 for the second time in two years. Shawn Miele, ... Inc. 5000 rankings for the second year in a row. It’s extremely difficult to make ...
(Date:8/17/2017)... ... August 17, 2017 , ... Navigating ... a Florida-based oncology business advisor to oncology practices, announced today the results of ... of attributable savings from resolving critical clinical issues that would have otherwise resulted ...
(Date:8/16/2017)... , ... August 16, 2017 , ... An August 3rd article on Reuters ... subject of a report in JAMA (the Journal of the American Medical Association). The study ... able to achieve BMIs under 30, when compared to patients with lower BMIs. At present, ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... list represents a unique look at the most successful companies within the American economy’s ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
Breaking Medicine Technology: